Cyclic stretch-induced VEGF expression is mediated by TGF-β in retinal pigment epithelial cells

CURRENT STATUS: POSTED

Wu Liu  wuliubj@sina.com
Department of Ophthalmology Beijing Tongren Eye Center Beijing Tongren Hospital
Capital Medical University Beijing Ophthalmology and Visual Sciences Key Lab Beijing
China
Corresponding Author
ORCiD: 0000-0001-7967-6924

Jinqiu Chen
Beijing Tongren Hospital

Shen Wu
Beijing Tongren Hospital

Jingxue Zhang
Beijing Tongren Hospital

Qian Liu
Beijing Tongren Hospital

Xida Liang
Beijing Tongren Hospital

Zengyi Wang
Beijing Tongren Hospital

Yanping Yu
Beijing Tongren Hospital

Jing Wang
Beijing Tongren Hospital

DOI: 10.21203/rs.2.309/v1

SUBJECT AREAS
Internal Medicine Specialties

KEYWORDS
Mechanical cyclic stretch; vascular endothelial growth factor; retinal pigment epithelium; transforming growth factor-beta; mitogen-activated protein kinase; vitreomacular adhesion
Abstract

**Background:** Vitreomacular adhesion (VMA) has been theorised to be a prospective risk factor for anti-vascular endothelial growth factor (VEGF) therapy. The mechanisms underlying VMA are not fully understood. Therefore, we investigated whether exposure to cyclic stretch was associated with increasing VEGF and related signalling pathways in vitro.

**Methods:** A cyclic stretch model of adult retinal pigment epithelial cell line-19 (ARPE-19) was conducted using a Flexcell-5000 strain system at a regimen of 10% prolongation stretch (1/2 sine, 1Hz). We observed the effect of cyclic stretch on VEGF and transforming growth factor-β (TGF-β) by using western blot and real-time polymerase chain reaction (PCR) for 3 h, 6 h, 9 h and 12 h. Enzyme-linked immunosorbent assay was used to measure the secretion of VEGF in the supernatant. To quantitatively detect the angiogenesis capacity of VEGF in vitro, tube formation assay was performed. The effects of TGF-β receptor I inhibitor SB335242 on stretch-induced VEGF protein expression and secretion were evaluated by western blot and ELISA. Components of the p38 mitogen-activated protein kinase (MAPK) and c-Jun NH2-terminal kinase (JNK) in the stretch group were analysed using western blot.

**Results:** We discovered that cultured ARPE-19 undergoing cyclic stretch significantly increased VEGF and TGF-β in a time-dependent manner and tube formation. Stretch-induced VEGF expression was inhibited by TGF-β receptor I inhibitor SB335242. In vitro, we also verified P38 MAPK and JNK expression. In western blot analysis, mechanical stretch evaluated P38 and JNK protein expression.

**Conclusion:** In this study, we first demonstrated that cyclic stretch induces the increasing VEGF through TGF-β in RPE cells. Mechanical stretch stimulates VEGF in a time-dependent manner and maintains angiogenesis ability. It is thus possible that RPE cells under
mechanical stretch, such as VMA, may generate high levels of TGF-β. Sequentially, the overexpressed TGF-β stimulates VEGF production, triggering CNV events and aggravating wAMD.

**Keywords:** Mechanical cyclic stretch; vascular endothelial growth factor; retinal pigment epithelium; transforming growth factor-beta; mitogen-activated protein kinase; vitreomacular adhesion.

**Introduction**

Age-related macular degeneration (AMD) is the leading cause of central blindness in the elderly population of the western world[1]. The most severe vision loss occurs in patients with neovascular AMD, known as wAMD[2]. Currently, the major anti-vascular endothelial growth factor therapies (anti-VEGF) are ranibizumab, bevacizumab and aflibercept[3]. Although anti-VEGF therapy has greatly changed the paradigm of wAMD treatment, it remains a challenge for non-response patients[4]. Several risk factors exist for non-response anti-VEGF, including single-nucleotide polymorphisms (SNPs), complement factor H (CFH), VEGF-A genes[5], choroidal neovascularisation (CNV) lesion and initial reading ability[4]. Recently, vitreomacular adhesion (VMA) has been theorised to be a prospective risk factor for anti-VEGF therapy. This hypothesis has been inferred from several studies that reported a broad influence of anti-VEGF therapy efficiency in eyes affected by VMA compared with age-matched controls[2, 6-10]. VMA was found to be located in the area of choroidal neovascularisation (CNV)[11, 12].

Although the mechanisms underlying the aggregation of these conditions by VMA are not well understood, VEGF has been strongly implicated as a primary mediator in anti-VEGF therapy efficiency. VEGF is the principal stimuli for raising angiogenesis in the improvement of CNV and other neovascularisation disorders[13]. In vivo, mechanical stretch can increase the expression of VEGF in human retinal pigment epithelium (RPE)
cells. Wu et al.[14] studied stretch-induced VEGF expression upregulated in an increment of approximately 25% strain in adult retinal pigment epithelial cell line-19 (ARPE)-19 cells. Similarly, Seko et al.[15] found that in rat RPE cells, VEGF could rapidly increase loaded with 15% elongation.

The molecular mechanisms underlying stretch-induced VEGF expression have not been researched extensively. Transforming growth factor beta (TGF-β) mediates stretch-induced VEGF expression in pulmonary arterial smooth muscle cells[16], coronary[17] and cardiac myocytes[18]. TGF-β is a pleiotropic cytokine that binds to membrane receptors bearing serine/threonine kinase activity, namely TGF-β receptors type I and II[19]. Binding of the active form of TGF-β to TGF-β receptor type II initiates phosphorylation of TGF-β receptor type I, which is followed by the phosphorylation regulation of the Smad-dependent and Smad-independent pathways[20, 21]. To date, the most extensively studied isoforms of TGF-β have been isoforms 1[22] and 2[23]. The signalling pathways that act downstream of TGF-β include canonical (Smads) and noncanonical (e.g., c-Jun NH2-terminal kinase [JNK]/p38 mitogen-activated protein kinase [MAPK], extracellular signal-regulated kinase-1/2 [ERK1/2], etc.) pathways[24]. In the eyes, TGF-β appears to be related to cell growth, differentiation, apoptosis and angiogenesis[25-30]. More importantly, TGF-β has been reported to stimulate strong VEGF expression through mitogen-activated protein kinases (MAPKs) in RPE cell culture[28].

In this study, we examined the mechanism of stretch-induced VEGF expression in RPE cells. This is the first study to demonstrate that stretch-induced VEGF expression is mediated by a TGF-β dependent pathway. Moreover, RPE cell exposure to cyclic stretch promoted P38 mitogen-activated protein kinase (MAPK) and JNK activation.

Methods

2.1 Culture of ARPE-19 cells and human umbilical vein endothelial cells (HUVECs)
The ARPE-19 cells were cultured as described previously [14]. The normal ARPE-19 cells purchased from the American Type Culture Collection (ATCC) were cultured in Dulbecco’s Modified Eagle Medium/Ham’s Nutrient Mixture F12 (1:1) (DMEM/F12, Gibco, Grand Island, NY) containing 10% foetal bovine serum (FBS, Gibco, Australia) and 1% penicillin-streptomycin (Gibco, Grand Island, NY) in a humidified incubator at 37°C at 5% CO$_2$. The medium was replaced every two or three days.

HUVECs were purchased from ATCC and were grown under the manufacturer’s recommendation using Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco, Grand Island, NY) supplemented with 10% foetal bovine serum (FBS, Gibco, Australia) and 1% penicillin-streptomycin (Gibco, Grand Island, NY). Cells of passages 2 through 7 were used for experiments. Cells were grown at 37°C in a humidified incubator with 5% CO$_2$.

2.2 Application of cyclic stretch

After removal of culture medium, ARPE-19 cells were harvested for seedlings on 6-well Flexcell culture plates coated with collagen type I (Flexcell International Corporation, Burlington, CA, USA). ARPE-19 cells were seeded in rubber membrane (Fig. 1A). And then using DMEM with 1% FBS serum starved until reaching subconfluency. Subsequently, ARPE-19 cells in fresh 1% FBS media were subjected to a cyclic stretch regimen of 10% prolongation stretch (1/2 sine, 1Hz) using a Flexcell® FX-5000 Tension system (Flexcell International Corporation, Burlington, CA, USA). Vacuum drawn through the Loading post pulls the rubber membrane downward at 37°C in a 5% CO$_2$ (Fig. 1B). Cells and supernatant were collected at different time points.

2.3 Quantitative real-time PCR

According to the manufacturer’s instructions, total RNAs were extracted using Trizol (Invitrogen, USA). The purity and concentration of RNA were measured by the ultraviolet
spectrometer at an optical density ratio of 260/280 (OD260/OD280). Then, total RNA was treated with RNase-Free DNase (Thermo, Pittsburgh, PA). First-strand cDNA was synthesised by reverse transcriptase from 5 μg total RNA with oligo-d (T) primers. Real-time PCR was performed by using an iCycler IQ real-time PCR detection system (Thermo, Pittsburgh, PA) to measure the fluorescence produced by SYBR Green I (Thermo, Pittsburgh, PA). The negative control was obtained by performing PCR without cDNA. The thermal cycling conditions were: 3 min at 95°C, followed by 40 cycles at 95°C for 30 sec, 57°C for 30 sec and 72°C for 30 sec. All PCR reaction products were verified by melting curve analysis. TGF-β mRNA is consistent with TGF-β1 mRNA and TGF-β2 mRNA. TGF-β and VEGFA mRNA expression levels were quantified by calculating the average value of triplicate reactions, normalised by the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primer sequences are shown in Table 1.

2.4 Western blot

Antibodies used in this study are listed as follows: VEGF165 (1:1000, ab1316, Abcam), TGF-β 1+2 (1:1000, ab124894, Abcam), P38 MAPK (1:2000, 8690S, Cell Signalling Technology), JNK (1:2000, 9252S, Cell Signalling Technology), Smad2/3 (1:1000, ab207447, Abcam), ERK1/2 (1:1000, ab36991, Abcam) and GAPDH (1:5000, ab8245, Abcam)

The protein concentration of the supernatant was measured by a BCA Protein Assay Kit (CWBIO, CHINA). Equivalent amounts of total proteins (30 μg) were loaded on 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gel after transferring to polyvinylidene difluoride (PVDF) membrane. Then, the membranes were incubated with primary antibody. The secondary antibody was goat anti-rabbit immunoglobulin G/horseradish peroxidase (IgG HRP)-conjugated (1:5,000) or goat anti-mouse IgG (HRP)-conjugated (1:5,000) All western blots were developed by HRP with the detection reagent
Western Lightning Plus ECL (Merck, Waltham, MA). Band densities were quantified using ImageJ software (National Institutes of Health, Bethesda, MD). These data were normalised by GAPDH expression.

2.5 Enzyme-linked immunosorbent assay [31]

Samples were performed using the Quantikine Human VEGF ELISA Kit (R&D Systems, Minneapolis, MN). An aliquot of 200 µl of conditioned medium was used per well. The levels of antigenic VEGF in the serial dilutions of ARPE-19 supernatants were quantitated by modification of a double ligand ELISA.

2.6 Tube formation assay

Tube formation assay was performed by the published protocol by Bai[32]. Aliquots of 100 µl of Matrigel (Cat#356231, BD Sciences) were added to each well of the 48-well plates, followed by incubation at 37°C for 30 min. The HUVECs (5 × 10⁴) were seeded to the top of solidified Matrigel with 150 ul of conditioned medium for 3 h at 37°C. Before start of the assay, the HUVECs can be treated with calcein AM (ab141420, Abcam) to visualise the cells using fluorescence[33]. On five photographs in each group, fields of the Matrigel were randomly chosen under the microscope, and the length of the tubes was easier quantitated using Image J Pro (National Institutes of Health, Bethesda, MD). The experiments were repeated three times.

2.7 Statistical analysis

Data are expressed as mean ± SEM. Significant differences between groups were ascertained by one-way analysis of variance (ANOVA) in combination with all pair wise multiple comparison procedures using Bonferroni test. In all cases, values of p < 0.05 were considered as statistically significant.

Results
3.1 Characterisation of stretch-induced VEGFA and TGF-β expression in ARPE-19 cells

ARPE-19 cells were subjected to an instance of 10% cyclic stretch for the durations indicated in Fig. 2A. Cyclic stretch maximally increased VEGFA mRNA expression 1.7-fold after 3 h and 6 h (p=0.001). Although VEGF mRNA levels gradually declined after that 6 h, stretch-induced VEGF mRNA significantly upregulated 1.3-fold after 9 h (p=0.023) and 1.2-fold after 12 h (p=0.043) compared with the control group. As shown in Fig. 2B, an increase in TGF-β mRNA expression was initially evident at 3 h, which peaked at 6 h when expression was 2.3±0.5-fold greater than in the control group (p=0.005).

To evaluate whether stretch-induced VEGF165 and TGF-β mRNA expression resulted in increased VEGF and TGF-β protein levels, western blot was used for analysis. As displayed in Fig. 3B, cyclic stretch increased VEGF165 expression in a time-dependent manner. VEGF165 expression was increased 1.1±0.07-fold (p=0.03), 1.2±0.03-fold (p=0.000) and 1.3±0.02-fold (p=0.000) after 6 h, 9 h and 12 h of cyclic stretch, respectively. The level of TGF-β protein expression was highest 1.8 times control value at 3h (P<0.01), and then declining to 1.2 fold (P<0.05) at 12h (Fig. 3C).

The secretion of VEGFA at different time points was detected by ELISA. The line graph showed that the level of VEGFA increased with the extension of a cyclic stretch (Fig. 3D). The average value was 3 h (499.85±10.963 pg/mL), 6 h (870.185±32.153 pg/mL), 9 h (1226.908±60.715 pg/mL) and 12 h (1761.053±37.873 pg/mL), respectively. There was a significant difference between the stretch group and the non-stretch group at each time point (P<0.05).

3.2 Evaluation of stretch-induced TGF-ββ signalling pathways

The relative expression of JNK protein was significantly higher than that of the same time at 3 h (1.162±0.075-fold), 6 h (1.171±0.043-fold), 9 h (1.226±0.013-fold) and 12 h
(1.1226±0.043-fold), respectively (p>0.05) (Fig. 4A-B). The relative expression levels of P38 MAPK protein in the stretch group at different time points were 3 h (1.214±0.056-fold), 6 h (1.312±0.044-fold), 9 h (1.216±0.05-fold) and 12 h (1.194±0.052-fold), which were significantly higher than those of the control group (P<0.01) (Fig. 4C).

3.3 Role of TGF-β in Stretch-induced VEGF Expression

The results in Figures 5A and 5B show that under the action of SB525334, the increase of VEGF165 expression induced by cyclic stretch was inhibited, which was significantly different from that of the non-inhibitor group (P<0.01); at the same time, there were no tension loading and blank control groups. In comparing (weakness without inhibitors), the relative protein expression of VEGF165 was also significantly reduced (P<0.05). With the prolongation of the action time, SB525334 exerted a continuously weakening effect on the traction force-induced VEGF secretion, and there was a statistically significant difference between the time points and the no inhibitor control group (P<0.01). To gain further insight into the potential expression, we detected the media by ELISA (Fig.5C). Treatment with SB525334 for a series time that could significantly inhibited VEGF expression (P<0.01). The average value was 3 h (0.16±0.028 fold), 6 h (0.17±0.013 fold), 9 h (0.2±0.016 fold) and 12 h (0.15±0.024 fold), respectively.

3.4 Stretch-induced VEGF stimulated HUVEC tube formation

Since the formation of tube-like structures is essential for angiogenesis[34], the ability of stretch-induced VEGF to promote tube formation was further investigated in Matrigel. Cultured HUVECs in vitro were incubated with the conditioned medium of the stretch group and control group for 3 h at 37°C in 5% CO₂. Typical tube-like structures were observed after fluorescent staining (Fig. 6A). The analysis by Image J software showed that the tube of length in the stretch group was significantly longer than that of the control group at 6 h (116±8%, P<0.05), 9 h (115±8%, P<0.05) and 12 h (127±4%,
P<0.01), respectively (Fig. 6B).

Discussion

Our study describes that cyclic stretch strongly increases VEGF expression in a time-dependent manner and promotes angiogenesis in human RPE cells. Meanwhile, stretch-induced VEGF expression is predominantly dependent on TGF-β and upregulates P38 MAPK and JNK cytokines.

Currently, the gold standard treatment for CNV is an intravitreal injection of anti-VEGF drugs, albeit with limited visual recovery in wAMD combined with VMA[4, 35]. Gao et al. [35] suggested that VMA traction had a significant influence on the treatment of anti-VEGF. Thus, a deeper understanding of VMA traction aetio-pathogeny is warranted.

Stemming from the application of Flexcell-5000 tension system to stimulate ARPE-19 cells, the expression and secretion of VEGF protein were significantly increased over time, while VEGF mRNA peaked at 6 h and then decreased slightly, indicating that mechanical stretch could regulate VEGF expression. The time course of VEGF expression in response to cyclic stretch in ARPE-19 was similar to that reported by Wu et al.[14], who also detected a sharp decrease after withdrawal of cyclic stretch. Seko et al.[15] found that VEGF expression was remarkably upregulated at 24 h in the 0.2 Hz 10% variability group, whereas it was increased at 1 h or 3 h in the 1 Hz 15% variability group in rat RPE cells. Compared with our results, these discrepancies may relate to the use of the older model device (Flexcell-3000 tension system) and the inconsistent mechanical parameters, or the use of rat cells rather than human cells.

In addition, we noticed that the higher concentration of VEGF measured by ELISA could significantly induce the differentiation of endothelial cells to tube-like cells, and length of the tube was dramatically longer than that of the control group. Since the formation of tube-like structures is essential for angiogenesis, these results indicate that cyclic stretch
could induce high expression of VEGF and has the potential to promote angiogenesis. CNV is an important pathological process in a variety of chorioretinal diseases, and both angiogenesis and vasculogenesis are involved[36]. Our study demonstrated cyclic stretch-induced VEGF expression could promote angiogenesis, which may partly illustrate the reason why the presence of VMA influences anti-VEGF efficacy. However, the mechanism of stretch-induced VEGF expression is unknown.

In other systems, including pulmonary arterial smooth muscle cells[16], coronary[17], rat cardiac myocytes[37] and heart[38] induce stretch-induced VEGF expression through a TGF-β mediated pathway. Our data revealed that the expression of TGF-β mRNA and protein significantly increased. Meanwhile, the peak of appearance time preceded the peak of VEGF. Our study is the first cell experiment detecting the mechanisms of stretch-induced VEGF expression in RPE cells. The upregulation of TGF-β may significantly indicate that it could participate in stretch-induced VEGF expression. Previous studies have reported that TGF-β strongly enhanced VEGF mRNA transcription and protein expression[39-41]. We report here that TGF-β receptor I inhibitor SB525334 could prevent stretch-induced VEGF expression over time. These findings indicated that TGF-β may work as a major intermediate in stretch-induced VEGF upregulation. Besides, a series of studies has confirmed that VEGF is the central link in promoting angiogenesis in the development of CNV[13], suggesting that mechanical stretch is a critical trophic factor for the expression of aberrant neovascularisation. In vivo, the TGF-β mRNA expression could be detected in retinal pigment epithelial cells, fibroblast-like cells and the endothelium of the neovascular region[39]. Also, TGF-β mediates collagen remodelling and scar contraction in the later stage of CNV, leading to scar tissue formation[42]. In an animal model, Nagineni et al.[28] showed that a high level of TGF-β is present in the retina of CNV patients, and Wang et al.[43] reported that the TGF-β/Smad pathway may function as an angiogenesis
promoter in CNV development. These studies demonstrate that TGF-β plays a critical role in CNV development.

We further explored the potential pathway through which TGF-β was involved in stretch-induced VEGF expression. In this study, JNK and P38 MAPK were activated and shown significant time-dependence under cyclic stretch. In the previous studies, Xu et al.[44] used magnetite beads to apply strain force to RPE cells, and Eri et al.[45] used mechanical scrapers to confirm that P38 MAPK activation can be induced by mechanical stretch, which agrees with our results. However, none of them found the activation of JNK under any mechanical force. Moreover, Gao et al.[46] used a 20% elongation stretch for stimulation for 6 h and 24 h and failed to change the JNK expression. We suspect that the above-mentioned differences may be related to multiple mechanical stimulation models and mechanical parameters. Much remains to be elucidated regarding this mechanism.

Furthermore, there couldn’t ignore with regards to the use of ARPE-19 cells, given the departure in the expression of important RPE-specific genes, in comparison to human RPE cells such as primary cell lines and freshly isolated RPE cells.

In summary, the results first demonstrated that cyclic stretch induces the expression of TGF-β that in turn increases VEGF expression in RPE cells. Mechanical stretch stimulates VEGF in a time-dependent way and maintains angiogenesis ability. Furthermore, P38 MAPK and JNK appear to be upregulated following cyclic stretch. It is thus possible that RPE cells under mechanical stretch, such as VMA, may produce high levels of TGF-β. Sequentially, the overexpressed TGF-β stimulates VEGF production, triggering CNV events and aggravating wAMD. Therefore, these cues could explain the molecular mechanisms of non-response anti-VEGF therapy in vivo, suggesting that the release of VMA traction or TGF-β inhibitors might provide an alternative to traditional methods in the clinical field.
Conclusions

Mechanical stretch could induce VEGF expression in a time-dependent manner; these changes is mediated by TGF-β in RPE cells.

Abbreviations

VMA: vitreomacular adhesion; VEGF: anti-vascular endothelial growth factor; ARPE-19: A spontaneously arising RPE cell line derived in 1986 by Amy Aotaki-Keen from the normal eyes of a 19-year-old male who died from head trauma in a motor vehicle accident; TGF-β: transforming growth factor-β; PCR: real-time polymerase chain reaction; ELISA: Enzyme-linked immunosorbent assay; MAPK: mitogen-activated protein kinase; JNK: c-Jun NH2-terminal kinase; AMD: age-related macular degeneration; SNPs: single-nucleotide polymorphisms; CNV: choroidal neovascularisation; CFH: complement factor H; FBS: Fetal bovine serum; DMEM-F12: Dulbecco’s Modified Eagle Medium/Ham’s Nutrient Mixture F12; HUVECs: human umbilical vein endothelial cells; RPMI: Roswell Park Memorial Institute; ANOVA: One-way analysis of variance.

Declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

The datasets generated and analyzed during the current study available from the corresponding author on reasonable request.
Competing interests

All authors declare that they have no conflict of interest with this submission.

Funding

This work was supported by the National Natural Science Foundation of China(81541106), Beijing Natural Science Foundation(7164243), Basic-Clinical Research Cooperation Funding of Capital Medical University(16JL52).

Authors' contributions

Involved in the design of the study (JQ.C., W.L.); conduct of the study (JQ.C., S.W., J.Z., Q.L.); analysis of the data (JQ.C., S.W., W.L.); preparation of the manuscript (JQ.C., S.W., J.Z., Q.L., W.L.); and critical revision of the manuscript (JQ.C., S.W., W.L.). All authors read and approved the final manuscript.

Acknowledgements

Not applicable

References

1. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J, Eye Diseases Prevalence Research G: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004, 122(4):564-572.

2. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD et al: Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012, 119(12):2537-2548.
3. Wickremasinghe SS, Xie J, Lim J, Chauhan DS, Robman L, Richardson AJ, Hageman G, Baird PN, Guymer R: **Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD.** *Invest Ophthalmol Vis Sci* 2011, **52**(7):4072-4079.

4. Lux A, Llacer H, Heussen FM, Joussen AM: **Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions.** *Br J Ophthalmol* 2007, **91**(10):1318-1322.

5. Finger RP, Wickremasinghe SS, Baird PN, Guymer RH: **Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration.** *Surv Ophthalmol* 2014, **59**(1):1-18.

6. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, Group AS: **Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.** *Ophthalmology* 2009, **116**(1):57-65 e55.

7. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group MS: **Ranibizumab for neovascular age-related macular degeneration.** *N Engl J Med* 2006, **355**(14):1419-1431.

8. Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, Rubio RG, Lai P, Group HS: **Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.** *Ophthalmology* 2013, **120**(5):1046-1056.

9. Comparison of Age-related Macular Degeneration Treatments Trials Research G, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL, 3rd: **Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.** *Ophthalmology* 2012,
10. Investigators IS, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lottery AJ, Wordsworth S, Reeves BC: Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012, 119(7):1399-1411.

11. Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, Binder S: Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol 2007, 144(5):741-746.

12. Lee SJ, Lee CS, Koh HJ: Posterior vitreomacular adhesion and risk of exudative age-related macular degeneration: paired eye study. Am J Ophthalmol 2009, 147(4):621-626 e621.

13. Zhang P, Su Y, Liu F: The relationship between intervention in the CD40 signal pathway and choroidal neovascularization. Onco Targets Ther 2014, 7:263-267.

14. Wu S, Lu Q, Wang N, Zhang J, Liu Q, Gao M, Chen J, Liu W, Xu L: Cyclic stretch induced-retinal pigment epithelial cell apoptosis and cytokine changes. BMC ophthalmology 2017, 17(1):208.

15. Seko Y, Seko Y, Fujikura H, Pang J, Tokoro T, Shimokawa H: Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro. Invest Ophthalmol Vis Sci 1999, 40(13):3287-3291.

16. Black SM, Grobe A, Mata-Greenwood E, Noskina Y: Cyclic stretch increases VEGF expression in pulmonary arterial smooth muscle cells via TGF-1 and reactive oxygen species: a requirement for NAD(P)H oxidase. Conf Proc IEEE Eng Med Biol Soc 2004, 7:5053-5056.

17. Zheng W, Seftor EA, Meiningier CJ, Hendrix MJ, Tomanek RJ: Mechanisms of
coronary angiogenesis in response to stretch: role of VEGF and TGF-beta. Am J Physiol Heart Circ Physiol 2001, 280(2):H909-917.

18. Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi BZ: Vascular endothelial growth factor and its receptors. Faseb Journal Official Publication of the Federation of American Societies for Experimental Biology 1999, 13(1):9.

19. Shi Y, Massagué J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113(6):685-700.

20. Massague J: How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000, 1(3):169-178.

21. Miyazono K: TGF-beta/SMAD signaling and its involvement in tumor progression. Biol Pharm Bull 2000, 23(10):1125-1130.

22. Pardali E, Goumans MJ, ten Dijke P: Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol 2010, 20(9):556-567.

23. Pfeffer BA, Flanders KC, Guerin CJ, Danielpour D, Anderson DH: Transforming growth factor beta 2 is the predominant isoform in the neural retina, retinal pigment epithelium-choroid and vitreous of the monkey eye. Exp Eye Res 1994, 59(3):323-333.

24. Ikushima H, Miyazono K: TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010, 10(6):415-424.

25. van Meeteren LA, Goumans MJ, ten Dijke P: TGF-beta receptor signaling pathways in angiogenesis; emerging targets for anti-angiogenesis therapy. Curr Pharm Biotechnol 2011, 12(12):2108-2120.

26. Schlingemann RO: Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2004,
27. Watanabe D, Takagi H, Suzuma K, Oh H, Ohashi H, Honda Y: **Expression of connective tissue growth factor and its potential role in choroidal neovascularization.** *Retina* 2005, **25**(7):911-918.

28. Nagineni CN, Samuel W, Nagineni S, Pardhasaradhi K, Wiggert B, Detrick B, Hooks JJ: **Transforming growth factor-β induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: Involvement of mitogen-activated protein kinases.** *Journal of cellular physiology* 2003, **197**(3):453-462.

29. Amin R, Puklin JE, Frank RN: **Growth factor localization in choroidal neovascular membranes of age-related macular degeneration.** *Invest Ophthalmol Vis Sci* 1994, **35**(8):3178-3188.

30. Ogata N, Yamamoto C, Miyashiro M, Yamada H, Matsushima M, Uyama M: **Expression of transforming growth factor-beta mRNA in experimental choroidal neovascularization.** *Curr Eye Res* 1997, **16**(1):9-18.

31. Royen NV, Hoefer I, Buschmann I, Heil M, Kostin S, Deindl E, Vogel S, Korff T, Augustin H, Bode C: **Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation.** *Faseb Journal* 2002, **16**(3):432-434.

32. Bai Y, Liang S, Yu W, Zhao M, Huang L, Zhao M, Li X: **Semaphorin 3A blocks the formation of pathologic choroidal neovascularization induced by transforming growth factor beta.** *Mol Vis* 2014, **20**:1258-1270.

33. DeCicco-Skinner KL, Henry GH, Cataisson C, Tabib T, Gwilliam JC, Watson NJ, Bullwinkle EM, Falkenburg L, O’Neill RC, Morin A et al: **Endothelial cell tube formation assay for the in vitro study of angiogenesis.** *J Vis Exp*
34. Sonowal H, Pal PB, Shukla K, Ramana KV: *Aspalatone Prevents VEGF-Induced Lipid Peroxidation, Migration, Tube Formation, and Dysfunction of Human Aortic Endothelial Cells*. *Oxid Med Cell Longev* 2017, *2017*:2769347.

35. Gao M, Liu L, Liang X, Yu Y, Liu X, Liu W: *Influence of vitreomacular interface on anti-vascular endothelial growth factor treatment outcomes in neovascular age-related macular degeneration: A MOOSE-compliant meta-analysis*. *Medicine (Baltimore)* 2017, *96*(50):e9345.

36. Grossniklaus HE, Green WR: *Choroidal neovascularization*. *Am J Ophthalmol* 2004, *137*(3):496-503.

37. Seko Y, Seko Y, Takahashi N, Shibuya M, Yazaki Y: *Pulsatile stretch stimulates vascular endothelial growth factor (VEGF) secretion by cultured rat cardiac myocytes*. *Biochem Biophys Res Commun* 1999, *254*(2):462-465.

38. Li J, Hampton T, Morgan JP, Simons M: *Stretch-induced VEGF expression in the heart*. *J Clin Invest* 1997, *100*(1):18-24.

39. Bian ZM, Elner SG, Elner VM: *Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells*. *Exp Eye Res* 2007, *84*(5):812-822.

40. Recalde S, Zarranz-Ventura J, Fernandez-Robredo P, Garcia-Gomez PJ, Salinas-Alaman A, Borras-Cuesta F, Dotor J, Garcia-Layana A: *Transforming growth factor-beta inhibition decreases diode laser-induced choroidal neovascularization development in rats: P17 and P144 peptides*. *Invest Ophthalmol Vis Sci* 2011, *52*(10):7090-7097.

41. Yingchuan F, Chuntao L, Hui C, Jianbin H: *Increased expression of TGF-beta1 and Smad 4 on oxygen-induced retinopathy in neonatal mice*. *Adv Exp Med Biol*
2010, 664:71-77.

42. Ding X, Patel M, Chan CC: Molecular pathology of age-related macular degeneration. Progress in Retinal & Eye Research 2009, 28(1):1-18.

43. Wang X, Ma W, Han S, Meng Z, Zhao L, Yin Y, Wang Y, Li J: TGF-beta participates choroid neovascularization through Smad2/3-VEGF/TNF-alpha signaling in mice with Laser-induced wet age-related macular degeneration. Scientific reports 2017, 7(1):9672.

44. Hou X, Han QH, Hu D, Tian L, Guo CM, Du HJ, Zhang P, Wang YS, Hui YN: Mechanical force enhances MMP-2 activation via p38 signaling pathway in human retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol 2009, 247(11):1477-1486.

45. Takahashi E, Fukushima A, Haga A, Inomata Y, Ito Y, Fukushima M, Tanihara H: Effects of mechanical stress and vitreous samples in retinal pigment epithelial cells. Biochemical & Biophysical Research Communications 2016, 470(3):569.

46. Gao M, Wu S, Ji J, Zhang J, Liu Q, Yue Y, Liu L, Liu X, Liu W: The influence of actin depolymerization induced by Cytochalasin D and mechanical stretch on interleukin-8 expression and JNK phosphorylation levels in human retinal pigment epithelial cells. BMC ophthalmology 2017, 17(1):43.

Tables

Table 1 - Primer Sequences
| Gene          | Forward Primer                      | Reverse Primer                      |
|--------------|-------------------------------------|-------------------------------------|
| VEGFA        | TCTCTACCCCAAGTGCACG                 | AGCAATGCTCAGACGAGCTCCC             |
| (NM_001025366.2) |                                    |                                     |
| TGF-β1       | CCGTGGAATCTGAGACACCG              | CTCGAGGAAAGCTGAGGTC                 |
| (NM_000660.6) |                                    |                                     |
| TGF-β2       | CTTTGGATGCCGCTATTTG               | CTGCTGTGCTGAGTGTCTGA               |
| (NM_003238.4  |                                    |                                     |
|              | (NM_001135599.3)                  |                                     |
| GAPDH        | GCACCGTCAAGGCTGAGAAC             | TGGTGAAGACGCCAGTGGA                 |
| (NM_002046)  |                                    |                                     |

**Figures**
Figure 1

Schematic diagram of one well of a culture plate (A) shown from above, the rubber membrane coated with Collagen type I is drawn in non-stretch. Fig.1B showed that vacuum drawn through the Loading post pulls the rubber membrane downward in a cyclic stretch regimen of 10% prolongation stretch (1/2 sine, 1Hz).

Thereafter, cells and supernatant were collected at different time points.
Figure 2

Cyclic stretch increases VEGFA mRNA and TGF-β mRNA expression. VEGF mRNA (A) and TGF-β mRNA (B) expression showed a statistically significant time-dependent increase after normalization to the control group. The experiment was repeated three times with similar results. *P < 0.05, **P < 0.01.
Effect of cyclic stretch on VEGF and TGF-β protein A Western blotting analysis of stretch induced VEGF165 protein and TGF-β protein undergo stretch and non-stretch group. The location of a 24kd and 44kd are respectively shown in figure. Results are expressed as relative VEGF165 protein (B) and TGF-β (C) protein compared with control levels. D The collected supernatant was analyzed by ELISA to examine the levels of secreted VEGFA. Data was from three independent experiments. *P < 0.05, **P < 0.01.
Cyclic stretch increases P38 MAPK and JNK expression. A Western blotting analysis of stretch induced P38 MAPK, JNK, Smad2/3 and ERK1/2 in stretch and non-stretch conditions.
group. As is shown, P38 MAPK and JNK are respectively significant increasing compared with control group. Smad2/3 and ERK1/2 were not increased in any samples of stretch group. B-C Quantitative analysis of P38 MAPK and JNK abundance. Data was from three independent experiments. *P < 0.05, **P < 0.01.
Cyclic stretch-induced VEGF expression is TGF-β dependent ARPE-19 was exposed
to 10% elongation stretch for 3h in the present (+) or absence (-) of an antibody against TGF-β receptor I (SB525334, 20uM). A. Four groups’ cell lysates was subjected to western blot using and polyclonal antibody against VEGF165. B. Band density Quantitation of multiple experiments is shown. C. Stretch and SB525334 were started at the same time, and condition media was evaluated by ELISA compared with non-stretch or SB525334 group after 3h, 6h, 9h and 12h. The fold change was calculating by diving the control group. Date was from three independent experiments. *P < 0.05, **P < 0.01.
Fluorescence microscopy imaging and quantification of tube formation. Typical tube formation was seen in any of the samples with conditioned medium (A). The length of tube-like formation was evaluated by Image J software. Quantitative data are presented as mean ± SEM (n = 3) in (B). *P < 0.05, **P < 0.01.